Latest Share Purchase Plans News

Lynas Rare Earths reported a 20% revenue increase in FY25 driven by higher NdPr sales, yet net profit fell sharply amid ramp-up costs and market challenges. The company completed key growth projects and unveiled its Towards 2030 strategy focused on downstream expansion.

Dome Gold Mines Ltd invites eligible shareholders to participate in a $5 million Share Purchase Plan at $0.15 per share, aiming to fund the transition to production at its Sigatoka Sands Project and exploration of other Fijian assets.

Canterbury Resources has announced a non-renounceable Share Purchase Plan to raise up to $0.75 million at a discounted price of 2 cents per share, offering eligible shareholders a chance to increase their holdings without brokerage fees.

PlaySide reports a 25% revenue decline and a $12.1 million net loss in FY25, driven by fewer original IP launches and restructuring costs. The company raises capital and streamlines operations ahead of major 2026 game releases.

PlaySide Studios reported a significant revenue drop and EBITDA loss in FY25, driven by declines in original IP sales. However, the company is banking on new game launches and cost-cutting measures to fuel a turnaround in FY26.

PlaySide Studios reported a 25% revenue decline to $48.7 million for FY25, resulting in a $12.1 million net loss. The company is banking on new game launches and cost savings to reverse the downturn in FY26.

WCM Global Growth Limited reported a robust 53% rise in net profit for FY2025, driven by strong portfolio returns and a successful capital raise, prompting an increased final dividend and upward revision of future dividends.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Amplia Therapeutics has successfully raised A$2.65 million through its Share Purchase Plan, exceeding expectations and bolstering funding for pivotal clinical trials of its lead drug narmafotinib.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

Felix Group Holdings Ltd has launched a capped $1 million Share Purchase Plan (SPP) offering eligible shareholders a discounted entry to support its strategic acquisition of Nexvia Pty Ltd and fuel growth initiatives. This retail-focused SPP complements a larger institutional placement as Felix aims to expand its enterprise software footprint.